Robert Duggan Purchases 660,233 Shares of Pulse Biosciences (NASDAQ:PLSE) Stock

Pulse Biosciences, Inc (NASDAQ:PLSE) Director Robert Duggan acquired 660,233 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was purchased at an average cost of $19.69 per share, for a total transaction of $12,999,987.77. Following the completion of the acquisition, the director owned 48,211,433 shares in the company, valued at approximately $949,283,115.77. This represents a 1.39% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Pulse Biosciences Price Performance

Shares of NASDAQ PLSE opened at $23.30 on Wednesday. The stock’s fifty day moving average price is $20.93 and its two-hundred day moving average price is $17.64. Pulse Biosciences, Inc has a one year low of $12.56 and a one year high of $26.30. The firm has a market cap of $1.59 billion, a price-to-earnings ratio of -21.18 and a beta of 1.63.

Pulse Biosciences (NASDAQ:PLSE) last announced its earnings results on Monday, May 4th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.05. The business had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.25 million. On average, equities analysts anticipate that Pulse Biosciences, Inc will post -1.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on PLSE. Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a report on Tuesday, April 21st. Wall Street Zen raised Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, February 21st. Oppenheimer reissued an “outperform” rating and set a $30.00 target price on shares of Pulse Biosciences in a report on Friday, February 20th. Finally, Mizuho set a $30.00 target price on Pulse Biosciences in a report on Friday, February 6th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $30.00.

Institutional Trading of Pulse Biosciences

Large investors have recently made changes to their positions in the company. Tudor Investment Corp ET AL acquired a new stake in Pulse Biosciences in the fourth quarter valued at about $382,000. Inspire Investing LLC lifted its holdings in shares of Pulse Biosciences by 33.4% in the fourth quarter. Inspire Investing LLC now owns 34,192 shares of the company’s stock worth $469,000 after acquiring an additional 8,561 shares during the last quarter. California State Teachers Retirement System lifted its holdings in shares of Pulse Biosciences by 23.2% in the fourth quarter. California State Teachers Retirement System now owns 21,165 shares of the company’s stock worth $291,000 after acquiring an additional 3,991 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of Pulse Biosciences by 13.8% in the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock worth $70,000 after acquiring an additional 619 shares during the last quarter. Finally, ExodusPoint Capital Management LP lifted its holdings in shares of Pulse Biosciences by 14.9% in the fourth quarter. ExodusPoint Capital Management LP now owns 25,122 shares of the company’s stock worth $345,000 after acquiring an additional 3,258 shares during the last quarter. Institutional investors and hedge funds own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.